Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
- PMID: 34220821
- PMCID: PMC8248497
- DOI: 10.3389/fimmu.2021.675307
Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
Abstract
Background: Reports on typical routine cerebrospinal fluid (CSF) findings are outdated owing to novel reference limits (RL) and revised diagnostic criteria of Multiple Sclerosis (MS).
Objective: To assess routine CSF parameters in MS patients and the frequency of pathologic findings by applying novel RL.
Methods: CSF white blood cells (WBC), CSF total protein (CSF-TP), CSF/serum albumin quotient (Qalb), intrathecal synthesis of immunoglobulins (Ig) A, M and G, oligoclonal IgG bands (OCB) were determined in patients with clinically isolated syndrome (CIS) and MS.
Results: Of 541 patients 54% showed CSF pleocytosis with a WBC count up to 40/μl. CSF cytology revealed lymphocytes, monocytes and neutrophils in 99%, 41% and 9% of patients. CSF-TP and Qalb were increased in 19% and 7% applying age-corrected RL as opposed to 34% and 26% with conventional RL. Quantitative intrathecal IgG, IgA and IgM synthesis were present in 65%, 14% and 21%; OCB in 95% of patients. WBC were higher in relapsing than progressive MS and predicted, together with monocytes, the conversion from CIS to clinically definite MS. Intrathecal IgG fraction was highest in secondary progressive MS.
Conclusions: CSF profile in MS varies across disease courses. Blood-CSF-barrier dysfunction and intrathecal IgA/IgM synthesis are less frequent when the novel RL are applied.
Keywords: albumin quotient; cerebrospinal fluid; cytology; diagnosis; immunoglobulin synthesis; multiple sclerosis; total protein; white blood cells.
Copyright © 2021 Berek, Bsteh, Auer, Di Pauli, Zinganell, Berger, Deisenhammer and Hegen.
Conflict of interest statement
KB has participated in meetings sponsored by and received travel funding from Roche and Biogen. GB has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Lilly, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche and Teva. MA received speaker honoraria and/or travel grants from Biogen, Merck, Novartis and Sanofi. FP has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. Her institution has received research grants from Roche. AZ has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Sanofi-Genzyme and Teva. TB has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Biogen, Biologix, Bionorica, Celgene, Eisei, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Teva, UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Aventis, Teva. FD has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Almirall, Alexion, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). HH has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Teva and Biogen.
Figures


Similar articles
-
Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z. J Neuroinflammation. 2017. PMID: 28851393 Free PMC article.
-
[Findings of cerebrospinal fluid in the diagnosis of multiple sclerosis].Srp Arh Celok Lek. 1995 Jul-Aug;123(7-8):191-3. Srp Arh Celok Lek. 1995. PMID: 17974427 Serbian.
-
CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort.Front Immunol. 2019 Mar 29;10:641. doi: 10.3389/fimmu.2019.00641. eCollection 2019. Front Immunol. 2019. PMID: 30984199 Free PMC article.
-
Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.J Neuroimmunol. 2006 Nov;180(1-2):17-28. doi: 10.1016/j.jneuroim.2006.07.006. Epub 2006 Sep 1. J Neuroimmunol. 2006. PMID: 16945427 Review.
-
An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Expert Rev Mol Diagn. 2017 Jan;17(1):31-46. doi: 10.1080/14737159.2017.1262260. Epub 2016 Dec 2. Expert Rev Mol Diagn. 2017. PMID: 27911122 Review.
Cited by
-
Microbiota, IgA and Multiple Sclerosis.Microorganisms. 2022 Mar 14;10(3):617. doi: 10.3390/microorganisms10030617. Microorganisms. 2022. PMID: 35336190 Free PMC article. Review.
-
Diagnostic uncertainty of steroid-modified Marburg's variant of multiple sclerosis even at autopsy: A case suggesting lymphoma and related myelin loss.eNeurologicalSci. 2024 Jul 11;36:100515. doi: 10.1016/j.ensci.2024.100515. eCollection 2024 Sep. eNeurologicalSci. 2024. PMID: 39108350 Free PMC article.
-
Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements.Biomolecules. 2022 May 7;12(5):677. doi: 10.3390/biom12050677. Biomolecules. 2022. PMID: 35625604 Free PMC article.
-
Comparing clinical features, severity and prognosis of autoimmune encephalitis and with and without oligoclonal bands.Front Neurol. 2024 Jan 5;14:1281276. doi: 10.3389/fneur.2023.1281276. eCollection 2023. Front Neurol. 2024. PMID: 38249729 Free PMC article.
-
Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective.Front Immunol. 2025 Mar 21;16:1547256. doi: 10.3389/fimmu.2025.1547256. eCollection 2025. Front Immunol. 2025. PMID: 40191184 Free PMC article. Review.
References
-
- Tourtellotte WW. The Cerebrospinal Fluid in Multiple Sclerosis. Handb Clin Neurol (1985) 47:79–130.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous